Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer - Université Côte d'Azur Accéder directement au contenu
Article Dans Une Revue Oncoscience Année : 2018

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer

Dates et versions

hal-02526788 , version 1 (31-03-2020)

Identifiants

Citer

Laetitia Seguin, Chloe C. Feral. Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer. Oncoscience, 2018, pp.124. ⟨10.18632/oncoscience.416⟩. ⟨hal-02526788⟩
29 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More